
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx is a clinical-stage biopharmaceutical company developing targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. Its patented Trans-Arterial Micro-Perfusion therapy platform allows for targeted delivery of treatments to the tumor site while minimizing toxicities, potentially leading to improved efficacy. The company has made positive progress in its clinical drug development and commercialization efforts with increasing centers utilizing its FDA-cleared RenovoCath. With the potential for strong revenue growth and a new CFO with a successful track record, RenovoRx has a strong outlook.
Bears say
RenovoRx is a clinical-stage biopharmaceutical company that has an attractive current valuation and has shown promising results in its TIGeR-PaC study. However, there are potential risks that could impact the company's ability to reach its share price target, including balance sheet and liquidity risks, potential failures in clinical trials, and competition in the market. Despite these risks, the company has a potential market worth billions of dollars, which could lead to high rewards for investors, making it an undervalued stock with a positive outlook for future growth.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares